StockNews.com upgraded shares of Lipocine (NASDAQ:LPCN – Free Report) from a hold rating to a buy rating in a research report released on Friday morning.
Lipocine Stock Up 1.5 %
LPCN opened at $4.84 on Friday. The company has a market cap of $25.88 million, a price-to-earnings ratio of -2.83 and a beta of 1.21. Lipocine has a 52-week low of $2.31 and a 52-week high of $11.79. The firm’s fifty day simple moving average is $4.58 and its two-hundred day simple moving average is $5.55.
Lipocine (NASDAQ:LPCN – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The business had revenue of $0.09 million for the quarter. On average, research analysts forecast that Lipocine will post -0.92 EPS for the current year.
Institutional Investors Weigh In On Lipocine
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Featured Articles
- Five stocks we like better than Lipocine
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What is the Nikkei 225 index?
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.